Precision Medicine in Oncology

As AI proliferates, patients, caregivers, and others outside the medical world are using its tools to deal with cancer, but not always in obvious ways.

This discussion will appear in the August issue of Evidence-Based Oncology.

With an FDA approval for its companion diagnostic in bladder cancer, Natera extends its Treatment on MRD strategy, deferring adjuvant immunotherapy for patients with negative results for disease following surgery.

Texas Oncology boosts precision medicine with near-universal biomarker testing, quality measurement, and genomic insights—advancing health equity through streamlined workflows and coverage. This commentary will appear in the June issue of Evidence-Based Oncology.

Todd Doyle, MD, of OneOncology, warns that commercial payers lag on updating bundled codes, which has slashed radiation oncology revenue and risks community cancer access in 2026.

Oncology leaders appearing in Atlanta, Georgia, including several from Winship Cancer Institute from Emory University School of Medicine, show how NGS biomarkers and MRD reshape NSCLC and hematology care, tackling payer hurdles and health equity gaps.

The editor in chief of Evidence-Based Oncology lauds Congress' authorization of a path for Medicare coverage for multicancer early detection.

The visual nature of head and neck cancer calls for treatment strategies that will minimize toxicities related to radiation therapy. Advances in precision radiation techniques, supportive care, and multidisciplinary approaches have improved outcomes, improving quality of life.

AI is poised to transform oncology with innovative tools enhancing diagnosis, treatment, and clinical trials, despite some wariness from clinicians and patients.

Precision oncology's promise was the key theme of the July 17 session of the Institute for Value-Based Medicine with faculty from multiple institutions in the Boston, Massachusetts area.

There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting the need for improved testing and targeted therapy integration.

Florida Cancer Specialists & Research Institute launches a new precision medicine venture; Tennessee Oncology announces promotions.

Coverage of clinical trial results presented across a range of solid tumor cancers, including breast, ovarian, colorectal, and non-small cell lung cancer, among other types; as well as important findings in genomic testing.

The therapy is designed to target multiple receptors and could address an unmet need in metastatic colorectal cancer.

Coverage from the American College of Cardiology Scientific Session Together With World Congress of Cardiology, held March 4-6, 2023, in New Orleans, Louisiana.

Miruna Sasu, PhD, MBA, became president and CEO of COTA Healthcare in March 2022, not quite a year after joining the company as its chief strategy officer. As the importance of RWD grows, Sasu is ready to take its use in precision oncology to new levels. She spoke with Evidence-Based Oncology™ (EBO) about her new role.

Development of FGFR inhibitors, which target fibroblast growth factor receptors, is among the most important advances in the treatment of cholangiocarcinoma.